D.E. Shaw & Co
CLSD

D.E. Shaw & Co’s Clearside Biomedical CLSD Stock Holding History

D.E. Shaw & Co’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,965
Closed -$366K – 3779
2018
Q3 		$366K Buy
+3,965
New +$471K ﹤0.01% 3275
2018
Q1 		– Sell
-875
Closed -$92K – 3519
2017
Q4 		$92K Buy
+875
New +$93.9K ﹤0.01% 3497

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's CLSD Position: Q4 2018 in Review

D.E. Shaw & Co sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 3,965 shares — an estimated $366K sold.

D.E. Shaw & Co first reported a position in CLSD in Q4 2017 and held it in 2 quarters. The position peaked at $366K in Q3 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

  • D.E. Shaw & Co reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 3,965 Clearside Biomedical shares in Q4 2018, an estimated $366K.
  • D.E. Shaw & Co first reported a position in Clearside Biomedical in Q4 2017 and held it in 2 quarters.
  • D.E. Shaw & Co's Clearside Biomedical position peaked at $366K in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on D.E. Shaw & Co's 13F filing for Q4 2018, filed 14 Feb 2019.